A 42-Year-Old Man Presents With Diarrhea

January 11th 2025

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

Roman Fabbricatore

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Natasha Bahri, MD, MS;Daneng Li, MD

December 30th 2024

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Tim Cortese

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Topical Gel Significantly Improves EGFR Inhibitor-Related Skin Toxicity

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Related Content

January 11th 2025

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Roman Fabbricatore

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD

December 30th 2024

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Tim Cortese

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.